B4GALT6

Across TCGA pan-cancer cohorts, B4GALT6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B4GALT6 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher B4GALT6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALT6 expression acts as an unfavorable survival marker.

BRCA, COAD, and UCEC are the cancer types where B4GALT6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.350	0.913	<.001	26	view →
COAD	DFS	Median	III,IV	0.233	0.658	.004	21	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →
SCLC	OS	Median	All	0.219	0.650	.031	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B4GALT6–BRCA (OS)

Open the BRCA breakdown →